CTLA-4 blockade-based anti-tumor immunity was augmented upon prior vaccination with autologous and irradiated tumor cells engineered to secrete GM-CSF, in patients suffering from metastatic melanoma or ovarian carcinoma (Hodi et al, 2008). Here, CSF2 is linked to ovarian carcinoma.